According to a recent McKinsey survey for the fourth quarter of 2025, 50% of healthcare organizations in the United States have implemented generative artificial intelligence (genAI) solutions. This milestone marks the first time that adoption has reached 50% since McKinsey began tracking this trend in 2023. The survey covers a wide range of entities, including healthcare providers, insurers, and health technology and services companies.
Artificial Health
The adoption of genAI is not only seen as a tool for management; in fact, 54% of organizations use this technology to improve clinical productivity, making it the most common use case. Potential applications include assistance in patient care, medical literature search, note transcription, and support in diagnostics. This underscores a significant shift towards the integration of advanced technologies in the clinical field.
A revealing fact is that 87% of healthcare organizations believe that genAI can have a significant impact on improving administrative efficiency. Although many organizations are still in the pilot phase, those that have already implemented genAI expect to achieve a return on investment (ROI) of between 2 and 4 times, especially through labor cost reduction and increased staff productivity.
However, measuring ROI in the clinical field presents challenges. This makes initial acceptance by physicians and user adoption crucial. According to a recent AMA survey, it is essential to have clear training materials and solid clinical evidence to support the use of genAI, highlighting accuracy in diagnostics and the interpretation of medical images.